Our Current Portfolio at a Glance
Our EXIS™️ platform drives a portfolio of fully human antibody therapeutics across multiple disease areas. We are currently advancing candidates in Immunology & Inflammation, Obesity & Metabolic Disorders, and Oncology, with plans to expand into new indications.
Programs& Their Components
Target CredentialingTar CredTarBiology + Development + Strategy
EXIS™️+ Antigen AIEXIS & AIEXISHit Discovery + Optimization
Lead OptimizationLead Opt. LeadCell Testing + Multispecific Design
Candidate SelectionCan. Sel.Sel.Animal Testing + early CMC
IND-EnablingINDINDFull PK/PD, Safety + GMP / CMC
Phase 1Ph. 1P1
Obesity
GIPR*/
GLP-1/
Glucagon
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Activin
RIIB
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Activin/
GLP-1/
Glucagon
Tar
EXIS
Lead
Sel.
ClinicIND
P1
GPR 75
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Immunology and Inflammation
IL-13/IL-31RA
Tar
EXIS
Lead
Sel.
ClinicIND
P1
IL-13/IL-18
Tar
EXIS
Lead
Sel.
ClinicIND
P1
IL-31RA/IL-18
Tar
EXIS
Lead
Sel.
ClinicIND
P1
OX40
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Oncology
CD3
Tar
EXIS
Lead
Sel.
ClinicIND
P1
SLC7A11
Tar
EXIS
Lead
Sel.
ClinicIND
P1
TCR-mediated targets
Tar
EXIS
Lead
Sel.
ClinicIND
P1
STEAP1
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Veterinarian
Canine NGF
Tar
EXIS
Lead
Sel.
ClinicIND
P1
Canine IL-31
Tar
EXIS
Lead
Sel.
ClinicIND
P1
— Clinically-Validates
— Novel Targets
* — Antagonist